Latest Us Market Access News

American Tungsten & Antimony Ltd (ASX: AT4) has raised A$10 million through a strongly supported placement and secured a 40% Utah state tax credit, underpinning its strategy to develop a domestic US supply chain for tungsten and antimony ahead of a planned Nasdaq listing.

Titomic Limited is set to shift its corporate domicile from Australia to the United States through a scheme of arrangement, aiming to deepen its US defense market presence and access broader capital pools while maintaining its ASX listing.

Dalaroo Metals has launched trading on the US OTCQB market, broadening its investor reach without diluting shares, while progressing its Greenland rare earth project with promising exploration results.

Amaero Ltd has announced plans to re-domicile from Australia to the United States, aiming to tap into larger capital markets and position itself for a potential US IPO by late 2026 or early 2027. The move retains its ASX listing while opening doors to broader investor pools and strategic growth opportunities.

Resolution Minerals has taken a significant step towards expanding its footprint in the US capital markets by lodging a registration statement with the SEC and launching an ADR facility, while divesting a non-core Alaskan asset to focus on key US projects.

Pharmaceutical manufacturer ANO has been hit with a US FDA Import Alert, joining several Australian peers amid wider regulatory tensions. The company is mobilising expert consultants and preparing a petition to lift the alert within weeks.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

4DMedical Limited has secured FDA clearance and immediate Medicare reimbursement for its groundbreaking CT – VQ™ lung imaging technology, accelerating commercial adoption across the US, Brazil, and Australia.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.